Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03096886 · ClinicalTrials.gov registry record · NA

Novel Neural Circuit Biomarkers of Major Depression Response to CCBT

A NA study, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
132
Enrollment target

NCT03096886: Completed NA study, sponsored by University of Pennsylvania.

NCT03096886 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 132 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03096886, a NA study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
132 participants
Enrollment target

Study Summary

The purpose of the study is to learn more about computer-assisted cognitive behavioral therapy or "CCBT" and to examine connections in the brains of patients with depression. CCBT is approved by the FDA as a form of treatment for depression. It is done partly on the computer and partly with a therapist. This study will enroll participants with depression and participants without depression. The investigators will recruit a total of 100 participants: 80 with Major Depressive Disorder (MDD) and 50 matched comparison participants. Healthy control subjects will participate for approximately 8 weeks. All MDD participants will receive CCBT. Half of the MDD participants will all receive computer-augmented skills training with the Good Days Ahead (GDA) protocol immediately (Early CCBT). Early CCBT subjects will participate for approximately 8 weeks. The other half of the MDD participants initially will be randomized to a waitlist of up to 4 weeks and subsequently will receive CCBT treatment (Late CCBT). Late CCBT subjects will participate for approximately 12 weeks. All participants are asked to complete a screening, which includes a series of clinical interviews and self-report questionnaires about the individual's thoughts, moods, and behaviors. All participants are asked to wear an actigraph, which is a watch-like device that measures activity levels. Additionally, participants are asked to completed short questions and have their activity levels monitored through phone app(s). All participants (Healthy Control and MDD participants) will receive functional magnetic resonance imaging (fMRI) scanning at baseline. Early CCBT participants will receive fMRI scanning after 8 weeks of CCBT, and Late CCBT participants will receive fMRI scanning at the conclusion of the waitlist and after the 8-week course of CCBT. Brain activity will be compared between MDD and controls at baseline and between Early CCBT vs Late CCBT. The 2nd and 3rd brain scans of Late CCBT participants at

Primary Outcome

Compare baseline resting state functional connectivity and task-induced activity between MDD (early and late CCBT combined) and controls. The connectivity values were Z-normalized Pearson's r values. Specifically, time series values were averaged across all voxels within each given Region Of Interest (ROI) (Left Dorsolateral Prefrontal Cortex and Subgenual Anterior Cingulate Cortex). For each study visit for each participant, the resulting region-wise time series values were then correlated with

Interventions

  • BEHAVIORAL Computer-Augmented Cognitive Behavioral Therapy

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2017-06-05
Est. Completion 2023-10-23
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT03096886 record still lists

NCT03096886 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Computer-Augmented Cognitive Behavioral Therapy is the first listed.

NCT03096886 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03096886 about?

NCT03096886 is a clinical study titled "Novel Neural Circuit Biomarkers of Major Depression Response to CCBT". The purpose of the study is to learn more about computer-assisted cognitive behavioral therapy or "CCBT" and to examine connections in the brains of patients with depression. CCBT is approved by the FDA as a form of treatment for depression. It is done partly on the computer and partly with a therap...

What is the current status of trial NCT03096886?

This trial is currently completed. It is a NA study. The enrollment target is 132 participants. The study started on 2017-06-05. Estimated completion is 2023-10-23.

What interventions are being tested in trial NCT03096886?

The interventions under investigation include: Computer-Augmented Cognitive Behavioral Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT03096886?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03096886's enrollment target sits among peer trials

132 729th of 2000 higher than 1,269 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03096886, the US trial registry maintained by the National Library of Medicine. NCT03096886 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.